URGN Stock Analysis: Buy, Sell, or Hold?
URGN - UroGen Pharma Ltd. Ordinary Shares
$42.31
0.07 (0.17%)
▲
5d:
-5.73%
30d:
-13.65%
90d:
+43.42%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When URGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: URGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: URGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$86.92
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$53.97
21.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: URGN is currently trading at $42.31, which is considered fair relative to its 30-day fair value range of $43.17 to $48.38. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.1) compared to its historical average (22.2). Remarkably, the market is currently pricing in an annual earnings decline of 12.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, URGN is in a strong uptrend. The price is currently testing key support at $41.60. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: URGN scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.00 (+41.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, URGN is in a strong uptrend. The price is currently testing key support at $41.60. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: URGN scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.00 (+41.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$43.17 -
$48.38
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
Protect Your Profits
Holding URGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 41.8% below Wall St target ($60.00)
- CAUTION: 5-day price weakness (-5.7%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$43.17 -
$48.38
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$41.60
Resistance Level
$47.06
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.14
Wall Street Target
$60.00
(+41.8%)
Revenue Growth (YoY)
199.2%
Profit Margin
-51.7%
Valuation Discount vs History
-12.0% cheaper
PE vs Historical
15.1 vs 22.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.0%
(market-implied from PE analysis)
1-Year Target
$38.08
(-10%)
2-Year Target
$34.27
(-19%)
3-Year Target
$30.84
(-27%)
3-Yr Target (if PE normalizes)
(PE: 15→22)
$45.22
(+7%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.1 to 22.2
Stabilization Target:
$62.03
(+46.6%)
PE Expansion Potential:
+46.6%
Share & Embed Analysis
Last updated: September 13, 2026 2:39 AM ET
Data refreshes hourly during market hours. Next update: 3:39 AM
Data refreshes hourly during market hours. Next update: 3:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is URGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
Advanced URGN Option Strategies
Professional options setups generated by AI based on today's URGN price and gamma walls.
